Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: This study aimed to evaluate the clinical effectiveness of combined aerosolized (AER) and intravenous (IV) polymyxin B in managing patients with hospital-acquired pneumonia (HAP) caused by carbapenem-resistant gram-negative organism (CRO).
Methods: This multicenter prospective cohort study was conducted across six intensive care units in municipal and above-municipal hospitals in Shaanxi, China, from January 1, 2021 to December 31, 2022. Patients with CRO pneumonia were categorized into the intravenous group (IV polymyxin B alone) and the combination group (AER plus IV polymyxin B). Primary outcomes included ICU mortality, 28-day mortality and bacterial clearance, while secondary outcomes included the duration of mechanical ventilation and length of ICU stay.
Results: A total of 64 patients were included in the study, with 29 receiving AER plus IV polymyxin B and 35 receiving IV polymyxin B alone. On the seventh day of treatment, the combination group showed a significant reduction in the APACHE II score (17.86 ± 5.03 vs. 19.17 ± 11.02, P = 0.041) and procalcitonin levels (1.27 ± 0.20 vs. 3.18 ± 0.69, P < 0.001) compared to the intravenous group. Additionally, the combination group exhibited a higher bacterial eradication rate (62.1% vs. 42.9%), lower ICU mortality (27.6% vs. 37.1%), shorter duration of mechanical ventilation (371.39 ± 68.97 h vs. 563.94 ± 100.25 h), and reduced ICU stay (34.41 ± 17.87 d vs. 35.03 ± 21.66 d), although the differences were not statistically significant.
Conclusions: In patients with CRO pneumonia, combination therapy resulted in significant reductions in APACHE II scores and procalcitonin, but did not lead to statistically significant improvements in clinical outcomes, compared to IV polymyxin B alone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijantimicag.2024.107427 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study.
J Antimicrob Chemother
August 2025
Department of Intensive Care Unit, Beijing Tiantan Hospital, Capital Medical University, No. 119 South Fourth Ring Road West, Fengtai District, Beijing 100070, China.
Objectives: The spread of carbapenem-resistant Gram-negative bacteria (CR-GNB) related to nosocomial infections is an important public health challenge, and polymyxins have become the last line of defence against CR-GNB. In this study, we aimed to compare the efficacy and safety of different polymyxins.
Methods: This retrospective cohort study included neurocritical care patients with CR-GNB pneumonia.
Acute kidney injury of intravenous colistin sulfate compared with colistimethate sodium: a real-world, retrospective cohort study.
BMC Infect Dis
August 2025
Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: The nephrotoxicity associated with polymyxins is a critical safety concern in clinical practice. The aim of this study was to compare the nephrotoxicity of patients treated with colistin sulfate (CS) and colistin methanesulfonate (CMS).
Methods: Data on inpatients who received intravenous colistin (CS) or colistin methanesulfonate (CMS) for over 72 h were collected from January to December 2023.
The comparison of three regimens of polymyxin B for the treatment of central nervous system infections caused by carbapenem-resistant bacteria: A retrospective cohort study.
J Infect Public Health
July 2025
Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; Research Center for Life Science and Human Health, Binjiang Institute, Zhejiang University, Hangzhou 310053, China; Key Laboratory of Novel Targets and Drug Study for Ne
Background: The prevalence of central nervous system infections caused by carbapenem-resistant organisms is on the rise, posing a growing threat to public health. Polymyxin is deemed as one of the "last resort" options. In this study, we analyzed the therapeutic efficacy of three dosing regimens of polymyxin B: intravenous (IV), intraventricular (IVT) or intrathecal (ITH) (denote as IVT/ITH), and IV combined with IVT or ITH (denote as combination therapy).
View Article and Find Full Text PDFCase Report: Polymyxin B-induced anaphylactic shock.
Front Pharmacol
June 2025
Department of Rehabilitation Medicine, Hebei General Hospital, Shijiazhuang, Hebei, China.
Rationale: Polymyxin B is a widely used antibiotic in clinical practice, and anaphylactic shock represents a severe adverse drug reaction. Reports of polymyxin B-induced anaphylactic shock are rare in the existing literature.
Patient Concerns: A 67-year-old male patient in the recovery phase of cerebral infarction presented with fever.
Intravenous combined with nebulized polymyxin B may be effective in treating carbapenem-resistant gram-negative bacilli hospital-acquired pneumonia: a retrospective cohort study.
Eur J Clin Microbiol Infect Dis
July 2025
Department of Intensive Care Unit, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Province, Hangzhou, China.
Objective: To compare the clinical efficacy and safety of intravenous polymyxin B versus the combination of intravenous and nebulized polymyxin B for treating carbapenem-resistant gram-negative bacilli hospital-acquired pneumonia (CRGNB-HAP), and to explore the risk factors affecting 28-day all-cause mortality.
Method: Our retrospective analysis was conducted on data from CRGNB-HAP patients treated in the intensive care unit (ICU) with either intravenous polymyxin B alone or in conjunction with nebulized polymyxin B between November 28, 2018 and May 6, 2024. The primary endpoint was 28-day all-cause mortality, while safety outcomes were also assessed.